Similar biotherapeutic products: overview and reflections.

Zayrho Desanvicente-Celis, Arley Gomez-Lopez, Juan Manuel Anaya

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

3 Citas (Scopus)

Resumen

Biotherapeutic products (BPs) have revolutionized medicine, changing the way we treat several pathologies such as autoimmune diseases and cancer, among others. Herein, we present an overview of similar BPs (SBPs), also called biosimilars, including the manufacturing process and regulatory aspects involved. The objective of developing an SBP is to manufacture a molecule that is highly similar to a reference BP by conducting a comparability exercise (CE) that can demonstrate similar safety and efficacy. This CE consists of quality, as well as nonclinical and clinical evaluation. A case-by-case analysis approach guided by scientific and objective standards must be the foundation for the SBP approval process. The establishment of a balance between a comprehensive CE for SBPs and their reference BPs, and the design of costeffective strategies to provide better access to BPs, should be the key goal for national regulatory authorities.

Idioma originalInglés estadounidense
Páginas (desde-hasta)1841-1857
Número de páginas17
PublicaciónImmunotherapy
Volumen4
N.º12
DOI
EstadoPublicada - dic 2012

All Science Journal Classification (ASJC) codes

  • Inmulogía y alergología
  • Inmunología
  • Oncología

Huella Profundice en los temas de investigación de 'Similar biotherapeutic products: overview and reflections.'. En conjunto forman una huella única.

Citar esto